Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001216992 | SCV001388817 | benign | Tuberous sclerosis 1 | 2023-12-01 | criteria provided, single submitter | clinical testing | |
Gene |
RCV001751408 | SCV001997459 | uncertain significance | not provided | 2020-01-02 | criteria provided, single submitter | clinical testing | In silico analysis, which includes protein predictors and evolutionary conservation, supports that this variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Genome- |
RCV001216992 | SCV002039810 | uncertain significance | Tuberous sclerosis 1 | 2021-11-07 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV003163667 | SCV003887356 | uncertain significance | Hereditary cancer-predisposing syndrome | 2022-11-06 | criteria provided, single submitter | clinical testing | The p.M1090V variant (also known as c.3268A>G), located in coding exon 21 of the TSC1 gene, results from an A to G substitution at nucleotide position 3268. The methionine at codon 1090 is replaced by valine, an amino acid with highly similar properties. This amino acid position is conserved. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |